Market Research Future (MRFR) has announced a new release on the Global Circulating Tumor Cell Market. The report presents a detailed analysis of the market’s likely growth trajectory and drivers over the forecast period from 2018 to 2023, based on a solid examination of the market’s growth over the past few years. According to the report, the Global Circulating Tumor Cells Market was valued at USD 9,393.1 mn in 2017 and is expected to rise to a valuation of USD 28,300 mn by the end of 2023.
Circulating Tumor Cells (CTC) are cancerous cells that break off from the original site of the cancer and spread throughout the body through the vascular system. These cells thus act as the “seed” for cancer metastases. The highly adverse prognosis for cancer with metastasis has resulted in an increasing interest in circulating tumor cells, as they can act as an early warning system for cancer metastasis.
The clinical significance of circulating tumor cells was first recognized in 1869, but serious medical research within the context of the modern structure of the healthcare sector began in the 1990s. These studies were inspired by calculations that showed that even small cancerous growths shedding cells at a small rate of less than 1% per day would produce enough circulating tumor cells in the bloodstream to be detectable.
Global Circulating Tumor Cell Market – Key Players
Some of the eminent leaders of the market include Greiner Bio-One International GmbH, Ikonisys Inc., Thermo Fisher Scientific, STEMCELL Technologies, SRI International, Miltenyi Biotec, QIAGEN Hannover (QIAGEN), Menarini Silicon Biosystems, F. Hoffmann-La Roche Ltd, Fluxion Biosciences, Inc., NanoString Technologies, Inc, GE Healthcare, Advanced Cell Diagnostics, Inc. (Bio-Techne Corporation), ApoCell, Celltraffix Inc., and Epic Lifesciences.
Get Free Sample @ https://www.marketresearchfuture.com/sample_request/1362
Global Circulating Tumor Cell Market – Segments
The Global Circulating Tumor Cells Market is segmented by technology, application, end use, and region in the report.
The global circulating tumor cell market is segmented on the basis of technology into CTC enrichment, CTC detection, and combined enrichment and separation of CTC.
On the basis of application, the global circulating tumor cell market is segmented into clinical, research, and drug development.
By end use, the CTC market is segmented into hospitals & clinics, research & academic institutes, and diagnostic centers.
Global Circulating Tumor Cell Market – Geographical Analysis
The North American region leads the circulating tumor cell market globally; the growth is largely supported by the U.S. with the increasing prevalence of types of cancer as consequences of the wrong lifestyle. Besides, technological advancements getting transpired in the medical science and biotechnology alongside the substantial healthcare expenditure support the market growth.
The European region stands as another lucrative market for the circulating tumor cell. The market is growing owing to the increasing number of cancer patients in the region. Furthermore, the proliferation of advanced treatment facilities alongside the availability of skilled medical professionals, and the government support for research & development drives the market in the region. Moreover, factors such as technological advancement and well-spread awareness among people towards cancer and its consequences drive the growth of the regional market.
The CTC market in the Asia Pacific region is emerging as a promising market owing to the increasing number of cancer patients. Factors substantiating market growth include the increasing prevalence of cancer, spreading awareness among people about cancer, and the availability of new treatment methods. Proliferating markets in China and India majorly contribute to the market growth in the region.
Industry/ Innovation/Related News:
In May 2018, CellMax launched a new clinical trial in an effort to validate its CTC screening test for colorectal cancer in the U.S.
September 17, 2018 – Scientists at the University of California, Los Angeles (US) published in the Proceedings of the National Academy of Sciences the study of a mechanism for characterizing the function of rare tumor cells which they have developed.
These researchers have created a quick and effective mechanism to measure how these cells perform functions that drive the disease, such as producing proteins that degrade tissue. Their findings could lead to more personalized treatments for people with cancer.
September 19, 2018 – ApoCell, Inc. (US), a leader global in specialty clinical Research Company involved in the capture and analysis of CTC, unveiled the biomarker results from the BEACON Phase 3 clinical trial utilizing Apocell’s proprietary circulating tumor cell enrichment system, ApoStream®. It is one of its own kind of publication that shows changes in a therapeutic target biomarker detected in CTCs that impacts overall survival in an important subset of metastatic breast cancer (MBC) patients.
Browse Complete 110 Pages Premium Research Report Enabled with Tables and Figures @ https://www.marketresearchfuture.com/reports/circulating-tumor-cell-market-1362
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.
Contact:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar
Pune – 411028
Maharashtra, India
+1 646 845 9312
Email: salesteam@marketresearchfuture.com
